BuTrans patches are transdermal, self-adhesive patches licensed for the treatment of constant, moderate, non-malignant pain when an opioid is necessary for obtaining adequate analgesia.
BuTrans patches contain buprenorphine and are available in 4 patch strengths: 5 μg/h, 10 μg/h, 15 μg/h and 20 μg/h. Either one or two patches of any strength may be applied simultaneously, for a total of eight dosage options up to a maximum of 40 µg/h.
Buprenorphine is incorporated into an adhesive polymer matrix (acrylate vinyl acetate), from which it is continuously released into the systemic circulation over 7 days.
BuTrans is not licensed for the treatment of acute pain.
- Evans HC, Easthope SE. Transdermal buprenorphine. Drugs 2003; 63: 1999-2010.